top of page

USFDA Med. Device: Guidance on Laser Products, Diagnostics, X-ray & Ultrasonic Diathermy Devices

Writer's picture: Sharan MuruganSharan Murugan

The Center for Devices and Radiological Health released multiple guidances earlier today (21-February-2023), related to "Laser Products, Diagnostics, X-ray & Ultrasonic Diathermy Devices".


In this guidance, FDA provides detailed recommendations on how to submit 510(k)s for diagnostic ultrasound devices and transducers and describes the types of modifications a diagnostic ultrasound device can make without requiring a premarket notification (510(k)).

Diathermy is the controlled production of "deep heating" beneath the skin in the subcutaneous tissues, deep muscles, and joints for therapeutic purposes.


As part of this guidance document, recommendations are provided for 510(k) submissions of ultrasonic diathermy devices, also referred to as physiotherapy devices. In addition, certain International Electrotechnical Commission (IEC) standards are recommended for generating information for these devices that can be used to support 510(k) submissions.


As part of this guidance, FDA seeks to align performance standards prescribed by Subchapter C (Electronic Product Radiation Control (EPRC)) with IEC standards, where applicable and offers recommendations on how to comply with the applicable requirements to the industry.


The term “Performance Standards” will be used to refer to these regulations collectively known as the Performance Standards for Diagnostic X-ray Systems and Their Major Components.

To assist small entities to comply with these changes in the performance standard, the FDA has prepared this Small Entity Compliance Guide.


Under the EPRC provisions of the FD&C Act, this document addresses only diagnostic x-ray equipment requirements and responsibilities related to Manufacturers and assemblers.


In this guidance, the FDA describes how it expects manufacturers to comply with FDA performance standards for laser products.

Comments


I Sometimes Send Newsletters

Thanks for submitting!

  • LinkedIn
  • Facebook
  • Twitter
  • Instagram

DISCLAIMER

The views expressed in this publication do not necessarily reflect the views of any guidance of government, health authority, it's purely my understanding. This Blog/Web Site is made available by a regulatory professional, is for educational purposes only as well as to give you general information and a general understanding of the pharmaceutical regulations, and not to provide specific regulatory advice. By using this blog site you understand that there is no client relationship between you and the Blog/Web Site publisher. The Blog/Web Site should not be used as a substitute for competent pharma regulatory advice and you should discuss from an authenticated regulatory professional in your state.  We have made every reasonable effort to present accurate information on our website; however, we are not responsible for any of the results you experience while visiting our website and request to use official websites.

bottom of page